| Rheumatoid Arthritis

Hulio vs Ruxience

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.

Deep comparison between: Hulio vs Ruxience with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRuxience has a higher rate of injection site reactions vs Hulio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Ruxience but not Hulio, including UnitedHealthcare

Category

Hulio

Ruxience

At A Glance

RouteSC injection

FrequencyEvery 1-2 weeks

ClassTNF-alpha inhibitor

RouteIV infusion

ClassCD20-directed cytolytic antibody

Indications

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Granulomatosis with polyangiitis
Microscopic Polyarteritis
Pemphigus Vulgaris

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some Rheumatoid Arthritis patients not taking concomitant MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile arthritis Patients 2 years of age and older: 15 kg to <30 kg: 20 mg SC every other week; >=30 kg: 40 mg SC every other week.

Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years weighing 17 kg to <40 kg: 80 mg Day 1, 40 mg Day 15, 20 mg every other week; weighing >=40 kg: 160 mg Day 1, 80 mg Day 15, 40 mg every other week.

Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis 80 mg SC initial dose, followed by 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.

Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.

Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.

Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.

Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.

Contraindications

—

Drug Interactions

1222View drug interactions

537View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, abdominal pain, flu syndrome, hyperlipidemia, back pain, hypercholesterolemia, hypertension, hematuria, alkaline phosphatase increased.

Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, severe hepatic reactions including acute liver failure.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).

Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.

Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.

Pharmacology

Adalimumab-fkjp is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammatory and immune responses in conditions including RA, JIA, PsA, AS, CD, UC, Ps, HS, and UV.

Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Hulio